Universal Registration Document Including The Annual Financial Report

Overview

The report presents OSE Immunotherapeutics' 2022 performance as a biotech development business, with consolidated revenue of €18,302 thousand, primarily from licensing and collaboration agreements. It highlights positive Phase 3 Atalante-1 results for Tedopi after checkpoint-inhibitor failure, ongoing Phase 2 programs, and initiation of the OSE-279 Phase 1/2 trial. The company reported 61 average monthly employees at December 31, 2022 and maintained a nine-member board with four women and five men. Its CSR charter describes governance, employee, environmental and ethical practices, while noting limited environmental impacts from its research-focused operations.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: Ends 31 December 2022
Publication date: 28 April 2023
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services